Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-15
2008-07-15
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000
Reexamination Certificate
active
11461189
ABSTRACT:
The invention is directed to a compound of the formula Iwherein the variables are as defined herein, ora stereoisomeric form thereof, mixture of stereoisomeric forms, in any ratio, or a salt thereof.Another aspect of the present invention is directed to a pharmaceutical composition comprising, a pharmaceutically effective amount of one or more compounds of formula I according to claim1in admixture with a pharmaceutically acceptable carrier.The invention is also directed to a method for effecting the prophylaxis and therapy of degenerative joint diseases such as osteoarthroses, spondyloses, cartilage loss following joint trauma or a relatively long period of joint immobilization following meniscus or patella injuries or ligament ruptures, diseases of the connective tissue such as collagenoses, periodontal diseases, wound healing disturbances and chronic diseases of the locomotory apparatus such as inflammatory, immunological or metabolism-associated acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism, for the treatment of ulceration, atheroscleroses and stenoses, and for the treatment of inflammations, cancer diseases, tumor metastasis formation, cachexia, anorexia, cardiac insufficiency and septic shock or for the prophylaxis of myocardial and cerebral infarctions, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound of formula I according to claim1, or a pharmaceutically acceptable salt, solvate or prodrug thereof.Furthermore the invention is directed to a method for preparing a compound of formula I.
REFERENCES:
patent: 5294621 (1994-03-01), Russell
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 6015912 (2000-01-01), Wang et al.
patent: 6207672 (2001-03-01), Thorwart
patent: 6573277 (2003-06-01), Thorwart
patent: 6815440 (2004-11-01), Thorwart
patent: 2003/0130257 (2003-07-01), Sheppeck et al.
patent: 2005/0245505 (2005-11-01), Aszodi
patent: 0606046 (1997-10-01), None
patent: WO 94/28889 (1994-12-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 03/089416 (2003-10-01), None
ISR of PCT/EP05/000417.
Borowski, et al., Ractivity of the Bis(dihydrogen) Complex [RuH2(n2-H2)2(Pcy3)2] toward S-Heteroaromtic Compounds. Catalytic Hydrogenation of Thiophene, Organometallics 2003, 22, 4803-4809.
Busolo, M., et al., The Biphasic Regioselective Hydrogenation of Benzo [b] Thiophene and Quinoline Catalyzed by Ru(II) Species, Derving From The Water Soluble Phosphine TPPTS (Tris-Meta-Sulfonato-Phenylphosphine and Stabilized By Nitrogen Donor Ligands, Journal of Molecular Catalysis A: Chemical 189 (2002) 211-217.
Creemers, E. et al., Matrix Metalloproteinase Inhibition After Myocardial Infarction, Circulation Research 89 (2001), 201-210.
Li Y, et al., Matrix Metalloproteinases in the Progression of Heart Failure Potential Therapeutic Implications, Drugs (2001) 61 (9) 1239-1252.
Massova, I., et al., Matrix Metalloproteinases: Structures, Evolution, an Diversification, The FASEB Journal (1998) 12, 1075-1095.
Michaelides, et al., Recent Advances in Matrix Metalloproteinase Inhibitors Research, Current Phamaceutical Design 5 (1999), 787-819.
Skiles, J., et al., The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase, Current Medicinal Chemistry 2001, 8, 425-474.
Sarah J. George, Therapeutic Potential of Matrix Metalloproteinase Inhibitors in Atherosclerosis, Expert Opinion on Investigational Drugs (2000), 9 (5), 993-1007.
T.H. Greene, et al., Protection For the Amino Group, Protective Groups in Organic Synthesis—Carbamates; Wiley-Interscience; 1999; pp. 502-537.
T.H. Greene, et al., Protection for the Carboxyl Group, Protective Groups in Organic Synthesis, Wiley-Interscience; 1999; pp. 369-407.
Yip, et al., Matrix Metalloproteinase Inhibitors: Applications In Oncology, Investigational New Drugs 17 (1999), 387-399.
Hofmeister Armin
Lampilas Maxime
Matter Hans
Schudok Manfred
Ort Ronald G.
SANOFI-AVENTIS Deutschland GmbH
Solola Taofiq A
LandOfFree
Thieno-imino acid derivatives for use as matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thieno-imino acid derivatives for use as matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thieno-imino acid derivatives for use as matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3904825